Dr. David Loeb graduated from Johns Hopkins University and then moved to New York and obtained his MD and PhD from the Columbia University College of Physicians and Surgeons. He returned to Johns Hopkins, where he completed his internship and residency in Pediatrics and his fellowship in Pediatric Hematology and Oncology. He joined the faculty at Johns Hopkins, where he practiced and performed research for 17 years. Dr. Loeb joined the faculty at Children’s Hospital at Montefiore (CHAM), where he serves as Director of Pediatric Hematology, Oncology, and Marrow & Blood Cell Transplantation, in 2017. He is also a member of the Department of Developmental and Molecular Biology at the Albert Einstein College of Medicine.
Dr. Loeb is Director of the Sarcoma Program and is a member of the Bone Marrow Transplant Program at CHAM. He also has expertise in the care of children with other solid tumors, with acute myeloid leukemia and in the application of immunotherapy to childhood cancer. Dr. Loeb has an active translational research laboratory focused on understanding bone tumor metastasis. His laboratory developed a clinically relevant mouse model of sarcoma metastasis, and has used this model to perform preclinical testing of novel agents that can interfere with this process. In addition, Dr. Loeb is also studying the role of an enzyme called RNA helicase DDX3 in Ewing’s Sarcoma biology, especially how this enzyme affects the repair of damaged DNA. Dr. Loeb is also actively involved in clinical research, including the development of radiopharmaceutical agents for the treatment of bone metastases and the development of a small molecule inhibitor of DDX3. He serves as the Coordinating Physician for an international Phase I study of an immune checkpoint inhibitor for pediatric solid tumors, and he has directed a clinical trial of reduced intensity haploidentical bone marrow transplantation for children with high risk solid tumors. As an offshoot of his laboratory work, Dr. Loeb is involved in the development of biomarkers of metastatic risk and of minimal residual disease in children, adolescents, and young adults with sarcomas.